Physician profile
Wendy Waldman
NPI 1285084723
$3,174.96
in general payments reported to CMS, 2019-2025
31 companies · $601 in 2025
The $601 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $177 · 2021: $832 · 2022: $651 · 2023: $531 · 2024: $382 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.58 | 2020-2023 | Liletta, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $276.59 | 2021-2025 | |
| Esperion Therapeutics, INC. | $268.74 | 2021-2022 | |
| Evofem Biosciences, INC. | $220.80 | 2020-2025 | Solosec, Phexx, Phexxi |
| Mayne Pharma Commercial LLC | $201.34 | 2021-2025 | |
| Hologic Sales and Service, LLC | $191.42 | 2020-2024 | Novasure, Acessa Provu System |
| Agile Therapeutics, INC. | $157.89 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $156.01 | 2020-2022 | |
| Coopersurgical, INC. | $143.27 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $113.42 | 2021-2025 | Slynd |
| Sage Therapeutics, LLC | $106.81 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $97.32 | 2024-2025 | Veozah, Cresemba |
| Myovant Sciences INC. | $78.78 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $78.03 | 2023-2024 | Myfembree |
| Scynexis, INC. | $68.23 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.44 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $58.11 | 2023-2025 | |
| Novo Nordisk INC | $50.31 | 2022-2025 | Wegovy, Saxenda |
| Shield Therapeutics INC | $44.44 | 2022-2023 | Accrufer |
| Merck Sharp & Dohme LLC | $39.94 | 2021 | |
| Exact Sciences Corporation | $30.85 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $24.42 | 2025 | Nexplanon |
| Millicent US INC | $23.86 | 2024 | Intrarosa, Femring |
| Medicem INC. | $23.25 | 2020 | |
| Ascend Therapeutics US, LLC | $22.73 | 2022 | |
| Channel Medsystems, INC. | $21.22 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.33 | 2025 | Qelbree |
| Avion Pharmaceuticals | $17.82 | 2023 | Balcoltra |
| Lupin INC. | $16.97 | 2020 | |
| Intuitive Surgical, INC. | $16.56 | 2020 | |
| Dysis Medical, INC. | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.